Lenire Sponsors Military Veterans Hearoes Tour
Lenire is sponsoring the 10th Annual Hearoes Tour to expand access to hearing and tinnitus care for U.S. veterans through free nationwide screenings and support.
Read More
Search Results for: Lenire
Neuromod Closes €10 Million Financing to Accelerate Commercialization of Lenire
Neuromod Devices Ltd. has secured €10 million in oversubscribed equity financing to expand the availability of its FDA-approved tinnitus treatment device, Lenire.
Read More
Real-World Study Measures Lenire’s Effectiveness in Treating Tinnitus
The study found Lenire’s real-world effectiveness in treating tinnitus to be consistent with clinical trial results.
Read More
Lenire Tinnitus Device Now a Treatment Option for US Veterans
Neuromod’s Lenire tinnitus device is available as a treatment option for U.S. veterans and other federal health services patients.
Read More
Case Study: Using Lenire on Patient With Acoustic Neuroma
In this case study, a clinical audiologist used Neuromod’s Lenire to treat a problem with tinnitus in a patient with acoustic neuroma.
Read More
Neuromod Devices’ Lenire Receives De Novo Approval from FDA
Neuromod Devices’ Lenire, a bimodal neuromodulation device, has received De Novo approval from the FDA to treat tinnitus. According to the company, Lenire is the first of its kind to receive FDA approval.
Read More
Lenire Tinnitus Device Now Available in Denmark
Neuromod Devices Ltd has reached an agreement with Specialklinikken Borgå ApS, a Danish provider of private care for tinnitus, to make its Lenire device available in Denmark.
Read More
Neuromod Publishes Clinical Trial for Lenire Device
An international team, including a University of Minnesota professor, has published a second large clinical trial for a novel neuromodulation device, Lenire, that could reduce symptoms for millions worldwide with tinnitus, commonly described as “ringing in the ears.” Researchers published the results of the Treatment Evaluation of Neuromodulation for Tinnitus – Stage A2 (TENT-A2) clinical trial in “Nature – Scientific Reports.” An article detailing the research appears on the University of Minnesota website.
Read More
Neuromod Announces Lenire Tinnitus Study Results
Neuromod Devices Ltd announced the findings of an independent study performed at the German Hearing Center (DHZ) at Hannover Medical School, which found that 85% of tinnitus patients experienced a reduction in their tinnitus symptoms (based on the Tinnitus Handicap Inventory score[i] across 20 patients) when using the Lenire treatment device.
Read More
Neuromod Raises $12.4 Million in Series B Funding for Lenire Tinnitus Treatment Device
The investment was led by majority investor Fountain Healthcare Partners, with participation from existing investors Moffett Investment Holdings and Medical Device Resources, with venture-debt provided by Kreos Capital and Silicon Valley Bank.
Read More
Neuromod’s Tinnitus Treatment Device Validated by Clinical Trial Results
Nature Communications published peer-reviewed results of Neuromod’s TENT-A3 clinical trial, validating its tinnitus treatment device, Lenire.
Read More
Neuromod Partners with University of South Dakota Clinic to Provide Tinnitus Treatment
Neuromod Devices is expanding access to its Lenire bimodal neuromodulation device, addressing the demand for effective tinnitus treatment.
Read More
Neuromod Devices Names New General Counsel
Neuromod Devices appointed Tom Maher as general counsel, bringing his extensive experience in the life sciences industry for the company.
Read More
Neuromod Expands Tinnitus Treatment Device Availability Via New Clinic Partnerships
Neuromod Devices expanded its U.S. presence by partnering with 14 new clinics to offer its FDA-approved Lenire tinnitus treatment device.
Read More
Neuromod’s Tinnitus Treatment Device Expands Availability in Spain
Lenire’s Spanish launch began in Barcelona. This latest expansion brings the number of clinics in Spain providing Lenire to four.
Read More